STOCKHOLM, December 29, 2017. Karolinska Development announces today that the company’s Chairman of the Board, Niclas Adler, has decided to leave his assignment for personal reasons. Professor Hans Wigzell, Board Director of Karolinska Development since 2006, takes over the role as Chairman of the Board.
Niclas Adler was elected Chairman of the Board at the company’s Annual General Meeting in May 2017. He has now announced to the Board that he leaves his position for personal reasons. Hans Wigzell takes over the position as Chairman of the Board.
Hans Wigzell, M.D., Professor Emeritus in Immunology, has been a Board Director at Karolinska Development since 2006, until 2013 serving as Chairman. Other assignments include Chairman of Rhenman & Partners Asset Management AB and Cadila Pharmaceuticals Sweden AB. He is also a Board Director of Sarepta Therapeutics Inc. and RaySearch Laboratories AB, and a member of the Royal Swedish Academy of Engineering Sciences (IVA) and the Royal Swedish Academy of Sciences (KVA). Previous assignments include, among others, President of the Nobel Assembly at Karolinska Institutet, President of Karolinska Institutet and Director General of the Swedish Institute for Infectious Diseases.
For further information, please contact:
Hans Wigzell, incoming Chairman of the Board, Karolinska Development AB
Phone: +46 70 576 05 39
Viktor Drvota, CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com
TO THE EDITORS
About Karolinska Development AB
Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients’ lives while providing an attractive return on investment to shareholders.
Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.
Karolinska Development has established a portfolio of nine companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.
The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.
For more information, please visit www.karolinskadevelopment.com
This information is information that Karolinska Development AB (publ) (Nasdaq Stockholm: KDEV) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of Viktor Drvota, at 19:30 CET on 29 of December 2017.
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/54bdcb17-7549-44c0-95a5-e5385325864c
